Logo Image
|Articles|November 19, 2019

FDA Approves Novartis Drug for Sickle Cell Disease Pain Treatment

The drug will be used to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

Novartis announced on Nov.15, 2019 that FDA approved Adakveo (crizanlizumab-tmca), previously known as SEG101, to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease, a genetic blood disorder.

Adakveo is the first FDA-approved medicine for sickle cell disease that binds to P-selectin, a cell adhesion protein that is crucial for the multicellular interactions that can lead to vaso-occlusion, according to Novartis.

According to a company press release, the approval was based on a 52-week, randomized, placebo-controlled trial, which concluded that the drug reduced the median annual rate of VOCs to 1.63 vs 2.98 compared to placebo (P=.010), a 45% reduction. The reductions were indifferent to sickle cell disease genotype and hydroxyurea use.

“We know this drug can decrease the frequency of sickle cell pain crises in a significant and clinically meaningful way,” said Kenneth Ataga, MD, director, Center for Sickle Cell Disease, University of Tennessee Health Science Center at Memphis, and principal investigator for the trial, in the press release. “The approval of crizanlizumab is an important advancement for people living with this very difficult condition.”

Other results from the trial included:

  • A 42% reduction in the median annual rate of days hospitalized to 4 vs 6.87 days when compared with placebo.

  • Of patients treated with the drug, 36% did not experience a VOC, compared to 17% of placebo-treated patients.

  • The median time to first VOC was 4.1 for Adakveo vs 1.4 months for placebo

“The approval of Adakveo marks a new era in the treatment of sickle cell disease, a genetic condition that places an extraordinary burden of unpredictable pain crises on patients and their families,” said Susanne Schaffert, PhD, president, Novartis Oncology, in the press release. “The stories we have heard from patients about their sickle cell pain crises are devastating. We are pleased to help reimagine medicine together with the sickle cell community and offer new hope for fewer VOCs.”

“Patients with sickle cell disease often face unique challenges, and have long suffered silently through unimaginable pain crises,” added Beverley Francis-Gibson, president and CEO of the Sickle Cell Disease Association of America, in the press release. “We are excited to have a new medicine that may help many of the thousands of people living with sickle cell disease by reducing the frequency of these potentially dangerous and painful episodes.”

Source: Novartis

 

 

 

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more